亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer

医学 转移性乳腺癌 肿瘤科 内科学 危险系数 乳腺癌 无进展生存期 癌症 靶向治疗 化疗 置信区间
作者
Lea Mollon,Elizabeth J. Anderson,Joni Dean,Terri Warholak,Ayal A. Aizer,Emma Platt,Derek Tang,Lisa E. Davis
出处
期刊:Clinical Breast Cancer [Elsevier BV]
卷期号:20 (3): e232-e243 被引量:38
标识
DOI:10.1016/j.clbc.2019.08.011
摘要

Abstract PIK3CA mutations may have prognostic value for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, representing an important potential target for systemic therapy. Prognostic and predictive values associated with PIK3CA mutations are not well understood. A comprehensive search of PubMed/MEDLINE, EMBASE, Cochrane Central, and conference abstracts was performed for English-language articles published January 1993 through April 2019. Articles were categorized by treatment arms based on experimental and treatment drug classes. Information on progression-free survival (PFS), hazard ratios, overall survival, response rate, and clinical benefit rate was obtained. A total of 17 studies were included. Among those evaluating non-PI3Ki based therapies, 91% showed numerically shorter median PFS, ranging from 1.5 to 19.2 months and 1.8 to 29.6 months for the mutant versus non-mutant subgroups, respectively. Where reported (n = 13 studies), PFS was shorter between those arms offering endocrine monotherapy (range, 1.6-14.7 months) compared with a corresponding targeted therapy + endocrine monotherapy (range, 3.9-29.6 months). Of 5 PI3Ki-based arms comparing PFS, higher median PFS in PIK3CA mutant versus non-mutant cases was demonstrated. PFS was shorter for patients with PIK3CA mutant (range, 1.6-19.2 months) compared with PIK3CA wild-type (range, 1.8-29.6 months) in 10 (71%) of 14 treatment arms reporting PFS. Studies (n = 4) not reporting PFS reported response rate, but there were no clear directional trends. The presence of PIK3CA mutations may be associated with worse clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Clinical outcomes such as PFS may be improved using a combination of PI3Ki-based therapies and endocrine therapies among this population. However, more research is warranted to fully elucidate this association.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
9秒前
pc完成签到 ,获得积分10
12秒前
14秒前
kaolatong发布了新的文献求助10
15秒前
SHD完成签到 ,获得积分10
34秒前
46秒前
发发发发发完成签到 ,获得积分20
47秒前
英姑应助梁山第一好汉采纳,获得10
52秒前
53秒前
肖影彤发布了新的文献求助10
58秒前
Oracle应助科研通管家采纳,获得200
58秒前
Leif完成签到 ,获得积分0
1分钟前
SciGPT应助kaolatong采纳,获得10
1分钟前
亚当完成签到 ,获得积分10
1分钟前
隐形曼青应助肖影彤采纳,获得10
1分钟前
jin1233完成签到 ,获得积分10
1分钟前
1分钟前
Yasmine完成签到 ,获得积分10
1分钟前
我是老大应助唠嗑在呐采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
头孢西丁完成签到 ,获得积分10
2分钟前
唠嗑在呐发布了新的文献求助10
2分钟前
罗嘉逸发布了新的文献求助200
2分钟前
2分钟前
肖影彤完成签到,获得积分10
2分钟前
唠嗑在呐完成签到,获得积分10
2分钟前
kaolatong发布了新的文献求助10
2分钟前
2分钟前
2分钟前
2分钟前
彭于晏应助kaolatong采纳,获得10
2分钟前
2分钟前
小胡爱科研完成签到 ,获得积分10
2分钟前
drsherlock应助梁山第一好汉采纳,获得10
2分钟前
2分钟前
天天快乐应助科研通管家采纳,获得10
2分钟前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 1500
Izeltabart tapatansine - AdisInsight 800
Maneuvering of a Damaged Navy Combatant 650
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3773648
求助须知:如何正确求助?哪些是违规求助? 3319141
关于积分的说明 10193255
捐赠科研通 3033772
什么是DOI,文献DOI怎么找? 1664646
邀请新用户注册赠送积分活动 796268
科研通“疑难数据库(出版商)”最低求助积分说明 757412